Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen to raise capital for Phase II Alzhimer’s disease clinical study

Actinogen to raise capital for Phase II Alzhimer’s disease clinical study

Actinogen (ASX:ACW) is progressing development of its novel treatments for Alzheimer’s disease and other major age-related neurodegenerative disorders.

The company has now been granted an ASX trading halt in relation to a capital raising for a Phase II study in Alzheimer’s dementia.

This will last until the earlier of the announcement being made or the start of trade on Friday, 24th April 2015.

Actinogen’s lead drug candidate Xanamem is being developed as a new therapy for Alzheimer’s disease.

Earlier this month, the company successfully dosed the second cohort of Phase I trial participants with 20mg of Xanamem.

This led to its being granted approval to escalate the dose to 35mg for the final cohort.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full ACW profile View Profile

Actinogen Medical Ltd Timeline

Newswire
December 30 2016

Related Articles

x-ray
February 02 2018
A first partnership agreement was signed with a South Korean company towards the end of 2017
People working in a laboratory
May 02 2018
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.
leg bones
March 31 2018
"We are now in the position of really trying to kick on in 2018"

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use